scispace - formally typeset
J

Jeffry D. Sander

Researcher at Harvard University

Publications -  45
Citations -  20137

Jeffry D. Sander is an academic researcher from Harvard University. The author has contributed to research in topics: Zinc finger & Transcription activator-like effector nuclease. The author has an hindex of 34, co-authored 44 publications receiving 18147 citations. Previous affiliations of Jeffry D. Sander include Howard Hughes Medical Institute & Iowa State University.

Papers
More filters
Journal ArticleDOI

High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells.

TL;DR: It is found that single and double mismatches are tolerated to varying degrees depending on their position along the guide RNA (gRNA)-DNA interface, and off-target cleavage of CRISPR-associated (Cas)9-based RGNs is characterized.
Journal ArticleDOI

CRISPR-Cas systems for editing, regulating and targeting genomes

TL;DR: A modified version of the CRISPR-Cas9 system has been developed to recruit heterologous domains that can regulate endogenous gene expression or label specific genomic loci in living cells, which will undoubtedly transform biological research and spur the development of novel molecular therapeutics for human disease.
Journal ArticleDOI

Efficient genome editing in zebrafish using a CRISPR-Cas system

TL;DR: It is shown that the CRISPR-Cas system functions in vivo to induce targeted genetic modifications in zebrafish embryos with efficiencies similar to those obtained using zinc finger nucleases and transcription activator-like effector nucleases.
Journal ArticleDOI

Improving CRISPR-Cas nuclease specificity using truncated guide RNAs

TL;DR: It is reported that truncated gRNAs, with shorter regions of target complementarity <20 nucleotides in length, can decrease undesired mutagenesis at some off-target sites by 5,000-fold or more without sacrificing on-target genome editing efficiencies.
Journal ArticleDOI

TALENs: a widely applicable technology for targeted genome editing

TL;DR: The newly-developed transcription activator-like effector nucleases (TALENs) comprise a nonspecific DNA-cleaving nuclease fused to a DNA-binding domain that can be easily engineered so that TALens can target essentially any sequence.